生物制剂及小分子靶向药治疗掌跖脓疱病研究进展

doi:10.12144/zgmfskin202409669

Abstract

Abstract: Palmoplantar pustulosis (PPP) is a chronic recurrent disease confined to the palmoplantar region, and there is no uniform standard of treatment. Targeted drugs and emerging drugs have been carried out in several clinical trials and case series studies. This paper reviews the progress of clinical research on PPP-related biologics and small molecule targeted drugs to provide a reference for further clinical treatment and related drug development.

Key words: biological agents, small molecule drugs, palmoplantar pustulosis, clinical trials, case series studies

YANG Yannan, WANG Junhui. Update of biologics and small molecule targeted drugs for the treatment of palmoplantar pustulosis[J].China Journal of Leprosy and Skin Diseases, 2024, 40(9): 669-673.

[1]	WANG Na, YANG Qing. Apremilast used in one case of palmoplantar pustulosis [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(8): 565-567.
[2]	GAO Xin, LI Mei, XIE Yan, YAN Pengrong, ZHAO Guowei. Palmoplantar pustulosis successfully treated with abrocitinib: a case report [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(7): 508-510.
[3]	JIAO Yuzhu, YANG Qing. Update of treatment of pyoderma gangrenosum [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(3): 216-220.
[4]	DU Baiyinzi, WANG Huiping, LUO Suju. Efficacy and safety comparation of adalimumab and secukinumab in the treatment of nail psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2024, 40(1): 26-30.
[5]	WANG Tianzi, LU Jiliang, LIU Yongxia, TIAN Hongqing. Three cases with palmoplantar pustulosis successfully treated by tofacitinib [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(6): 397-402.
[6]	DIAO Ziyue, XIA Ruiyuan, YIN Zhiqiang. Update of targeted therapy for localized pustular psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(6): 456-460.
[7]	XIE Han, ZENG Tongxiang. Update of biological agents in the treatment of nail psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2023, 39(1): 56-60.
[8]	CHEN Jie, BAO Jun. Application of biological agents used in China in special population with psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(3): 199-202.
[9]	MAO Mengmeng, BAI Bingxue. Update of the biological for treating hidradenitis suppurativa [J]. China Journal of Leprosy and Skin Diseases, 2022, 38(1): 56-59.
[10]	SUN Weina, LI Yuzhen. Update of treatment for erythrodermic psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(9): 614-617.
[11]	HU Zhonghui, SUN Qing. Update of biological agents in the treatment of psoriasis comorbidities [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(7): 471-476.
[12]	CHEN Jialin, LIU Guoyan, ZHOU Guizhi, TIAN Hongqing. Pityriasis rubra pilaris successfully treated with secukinumab: a case report and literature review [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(12): 783-786.
[13]	SUN Yonghu, ZHANG Furen. A child with psoriasis successfully treated with interleukin-17A antagonist and literature review [J]. China Journal of Leprosy and Skin Diseases, 2021, 37(1): 30-31.
[14]	XIANG Zhi, MA Yiping, CUI Pangen, CHEN Min. Effect of HLA-Cw6 allele on the efficacy of biological agents for the treatment of psoriasis [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(6): 321-326.
[15]	LIU Huiying, QI Jing, SONG Cuihao, WANG Rui, HUANG Min, XIE Fang, LI Chengxin. Efficacy of infliximab in the long-term treatment of psoriasis arthropathica [J]. China Journal of Leprosy and Skin Diseases, 2019, 35(12): 710-714.

Update of biologics and small molecule targeted drugs for the treatment of palmoplantar pustulosis

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10